Examining adherence to immunosuppressive medications in new liver transplant patients
Official title: A Prospective, Multi-center, Open-labeled, Randomized Clinical Trial of Patient Adherence and Convenience to Immunosuppressive Agents in Newly Liver Transplant Recipients to Compare QD Early Conversion and BID Tacrolimus Formulation.
Run by Chang Gung Memorial Hospital · NCT03216447 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing whether new liver transplant patients stick to taking their daily immunosuppressive medications better with a once-a-day pill compared to a twice-a-day pill.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Chang Gung Memorial Hospital Academic / other |
| Locations | 1 site (Taoyuan) |
| Trial ID | NCT03216447 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are primary liver transplant recipients aged 20 to 70 who can understand and follow study procedures.
✕Probably not a fit
Patients who have received other organ transplants or have certain medical conditions, such as requiring dialysis or being HIV positive, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates how well newly transplanted liver patients adhere to immunosuppressive medications, specifically comparing a once-daily formulation (Advagraf®) to a twice-daily formulation (Prograf). It is a prospective, multi-center, open-labeled, randomized clinical trial that will enroll participants in Taiwan. Patients will be randomized on postoperative day 15 to assess their adherence and convenience with the medication regimen. The study aims to improve patient outcomes by optimizing medication adherence in this population.
Why it matters
Potential benefit: If successful, this study could enhance medication adherence and improve health outcomes for liver transplant recipients.
How similar studies have gone: Other studies have shown that optimizing immunosuppressive medication regimens can improve adherence and outcomes, suggesting this approach has potential.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient has been fully informed and has signed an IRB approved informed consent form within 7 days (Day 7-13) prior to POD 15 and is willing and able to follow study procedure * Patient is a primary liver transplant recipient * Patient is 20 to 70 years of age * Patient should be clearly conscious, fully understand and able to answer questionnaire Exclusion Criteria: * Patient has previously received or is receiving an organ transplant other than a liver. * Patient currently requires dialysis * Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV) * Patient has received a liver transplant from a non-heart beating donor * Patient who is HCV negative has received an HCV positive (HCV RNA by PCR or HCV antibody) donor liver * Patient who is HbsAg negative has received an HbsAg positive (HBV DNA by PCR or HBV antibody) donor liver * Patient has received a liver transplant from a decrease donor \> 70 years of age * Patient has a current malignancy or a history of malignancy (within the past 5 years), except hepatocellular carcinoma within UCSF Criteria and basal or non-metastatic squamous cell carcinoma of skin that has been treated successfully. * Patient is hemodynamically unstable on POD 15
Where it's running
-
Chang Gung Memorial Hospital
Taoyuan, Taiwan Recruiting
Study contacts
- Principal investigator: Wei-Chen Lee — Cgmh
- Study coordinator: Wei-Chen Lee
- Email: weichen@cgmh.org.tw
- Phone: 09753-68195
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Everolimus-based calcineurin-free immunosuppression one year after liver transplant
This trial tests whether switching to or using everolimus with reduced calcineurin inhibitors after year one post-liver transplant can protect kidney function while maintaining graft health in adults at low rejection risk.
-
Sleep quality and its determinants during the liver transplant pathway
This study tests how sleep quality changes from before liver transplantation to six months after, in adults on the transplant waitlist at a single hospital.
-
Preoperative CIMT and Intraoperative Hemodynamics in Liver Transplant
This study looks at whether a higher carotid IMT measured before surgery is linked to more unstable blood pressure during liver transplant.
-
Reference framework for outcomes after machine-preserved liver transplantation in Europe
This study tests how liver transplants that use machine perfusion perform in real-world practice, to see how different perfusion methods relate to outcomes for adults in Europe.
-
Even protein distribution plus exercise for people awaiting liver transplant
This trial tests whether spreading daily protein evenly and combining it with a 12-week exercise program improves nutrition, muscle mass, and function in people waiting for a liver transplant compared with uneven protein timing or usual advice.
-
Preoperative Carbohydrate Loading Before Liver Transplant
This study tests whether drinking a carbohydrate beverage before anesthesia helps liver transplant patients recover faster.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.